loading page

Cardiovascular and renal safety outcomes of Hypoxia-inducible factor Prolyl-Hydroxylase Inhibitor Roxadustat for Anemia patients with chronic kidney disease: a systematic review and meta-analysis
  • +5
  • Lei Tian,
  • Mengdi Wang,
  • Mengchao Liu,
  • Yanyu Pang,
  • Jingwen Zhao,
  • Bingjie Zheng,
  • Yutong Wang,
  • Wenjing Zhao
Lei Tian

Corresponding Author:[email protected]

Author Profile
Mengdi Wang
Author Profile
Mengchao Liu
Author Profile
Yanyu Pang
Author Profile
Jingwen Zhao
Author Profile
Bingjie Zheng
Author Profile
Yutong Wang
Author Profile
Wenjing Zhao
Author Profile


This systematic review and meta-analysis were conducted to evaluate the cardiac and kidney-related adverse effects of Roxadustat for the treatment of anemia in CKD patients. 17 trials with a total of 6673 participants were identified for analysis. Meta-analysis revealed no significant difference in the risk of occurrence of cardiac disorders when comparing CKD patients receiving Roxadustat with the placebo group (RR=1.049; CI [0.918 to 1.200]) or ESA (RR = 1.099; CI [0.907 to 1.331]) group, in both dialysis-dependent (DD) (RR = 1.181; CI [0.925 to 1.507]) or non-dialysis-dependent (NDD) (RR = 1.036; CI [0.916 to 1.171]) CKD patients. No significant difference was observed in the risk of kidney-related adverse events when comparing groups receiving Roxadustat with the placebo group (RR=1.088; CI [0.980 to 1.209]) or ESA group (RR = 0.968; CI [0.831 to 1.152]), in DD (RR = 2.649; CI [0.201 to 34.981]) or NDD (RR = 1.053; CI [0.965 to 1.149]) CKD patients. No significant risk of hyperkalemia was observed in the Roxadustat group whether in DD (RR = 1.145; CI [0.756 to 1.734]) or NDD (RR = 1.116; CI [0.930 to 1.339]) patients. Incidence of hypertension was higher in the Roxadustat group, compared to the placebo group (RR = 1.374; CI [1.153 to 1.638]). In summary, the risk of cardiac or kidney-related events observed in the Roxadustat was not significantly increase whether in DD or NDD patients. However, attention must be paid to the occurrence of hypertension in patients using Roxadustat.